Findings from E. Matwejew and co-researchers advance knowledge in life sciences

A report, 'Maternal serum ADAM-12 as a potential marker for different adverse pregnancy outcomes,' is newly published data in Fetal Diagnosis and Therapy. According to recent research from Kiel, Germany, "To investigate first-trimester ADAM-12 levels in pregnancies which later develop hypertensive and growth complications. First-trimester serum samples (11(+0) to 13(+6) weeks) were retrieved from frozen storage. 47 samples with at least one of the following adverse outcomes: pre-eclampsia (PE), small for gestational age, HELLP syndrome and gestational hypertension were analysed and 452 controls matched to the cases by gestational age and length of storage were analysed."

...

Want to see the full article?

• Purchase this article for only $3.00